Business Context and Reporting Period
NewAmsterdam Pharma Company N.V. (NAMS) filed a Form 8-K on August 5, 2026, to announce corporate updates and financial results for the quarter ended June 30, 2026. The company is incorporated in The Netherlands and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that a press release containing these details is furnished as Exhibit 99.1, but the metrics themselves are not embedded in the 8-K text provided.
Material Changes
The filing does not contain data to compare current period performance against prior comparable periods. Specific material changes in financial condition or operations are referenced only as being contained within the attached press release (Exhibit 99.1).
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, risk factors, and contingencies are not detailed in the 8-K text. The filing explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of liability under the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 5, 2026) for actual financial figures and operational updates.
- Verify the specific details of the "corporate updates" mentioned in the filing header.
- Confirm the status of the company's ordinary shares (NAMS) and warrants (NAMSW) on Nasdaq.
- Note that the financial data in the press release is not incorporated by reference into this filing for liability purposes.